Trial Outcomes & Findings for Families-At-risk for Interstitial Lung Disease Study (NCT NCT03641742)

NCT ID: NCT03641742

Last Updated: 2023-11-18

Results Overview

The visual identification of the presence of ILA (Interstitial Lung Abnormalities) on CT chest scan by a thoracic radiologist.

Recruitment status

COMPLETED

Target enrollment

125 participants

Primary outcome timeframe

During imaging (up to 1 hour)

Results posted on

2023-11-18

Participant Flow

Participant milestones

Participant milestones
Measure
FAR-ILD Proband Participants
Historic data (from medical records) were reviewed.
FAR-ILD "At-Risk" Participants
Individuals underwent CT chest imaging and Pulmonary Function testing.
Overall Study
STARTED
27
98
Overall Study
COMPLETED
27
98
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Only 18 of 57 probands signed consent forms; their data is included here.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FAR-ILD Proband Participants
n=27 Participants
Historic data (from medical records) were reviewed.
FAR-ILD "At-Risk" Participants
n=98 Participants
Individuals underwent CT chest imaging and Pulmonary Function testing.
Total
n=125 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
n=5 Participants
89 Participants
n=7 Participants
96 Participants
n=5 Participants
Age, Categorical
>=65 years
20 Participants
n=5 Participants
9 Participants
n=7 Participants
29 Participants
n=5 Participants
Age, Continuous
68 years
n=5 Participants
52 years
n=7 Participants
54 years
n=5 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
61 Participants
n=7 Participants
71 Participants
n=5 Participants
Sex: Female, Male
Male
17 Participants
n=5 Participants
37 Participants
n=7 Participants
54 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
25 Participants
n=7 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
30 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
Ethnicity (NIH/OMB)
Not Hispanic or Latino
22 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
73 Participants
n=7 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
95 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
0 Participants
n=7 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
0 Participants
n=5 Participants • Only 18 of 57 probands signed consent forms; their data is included here.
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
1 Participants
n=5 Participants
2 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=5 Participants
2 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
White
22 Participants
n=5 Participants
72 Participants
n=7 Participants
94 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=5 Participants
21 Participants
n=7 Participants
24 Participants
n=5 Participants
Region of Enrollment
United States
27 participants
n=5 Participants
98 participants
n=7 Participants
125 participants
n=5 Participants
Interstitial Lung Abnormality (ILA)
27 Participants
n=5 Participants
0 Participants
n=7 Participants
27 Participants
n=5 Participants

PRIMARY outcome

Timeframe: During imaging (up to 1 hour)

The visual identification of the presence of ILA (Interstitial Lung Abnormalities) on CT chest scan by a thoracic radiologist.

Outcome measures

Outcome measures
Measure
FAR-ILD "At Risk" Participants Without ILA
n=98 Participants
The number of "At Risk" Participants whose Chest CT imaging, which was obtained as part of this study, did not show Interstitial Lung Abnormalities (ILA)
FAR-ILD "At-Risk" Participants With ILA
n=98 Participants
The number of "At Risk" Participants whose CT imaging, which was obtained as part of this study, showed evidence of Interstitial Lung Abnormalities (ILA)
Number of Participants With ILA (Interstitial Lung Abnormalities)
85 Participants
13 Participants

Adverse Events

FAR-ILD Proband With an Adverse Event

Serious events: 1 serious events
Other events: 0 other events
Deaths: 1 deaths

FAR-ILD "At-Risk" Participant With and Adverse Event

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
FAR-ILD Proband With an Adverse Event
n=27 participants at risk
Any adverse event resulting from participation in the study.
FAR-ILD "At-Risk" Participant With and Adverse Event
n=98 participants at risk
Any adverse event resulting from participation in the study.
Respiratory, thoracic and mediastinal disorders
Death due to respiratory cause
3.7%
1/27 • Number of events 1 • Adverse event data collected through study completion, an average of 1 year.
0.00%
0/98 • Adverse event data collected through study completion, an average of 1 year.

Other adverse events

Adverse event data not reported

Additional Information

Dr. Christine Kim Garcia

Columbia University Irving Medical Center

Phone: 2123058203

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place